RLAY VS VECT Stock Comparison

Performance

RLAY
10/100

RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

VECT
100/100

VECT returned 175.78% in the last 12 months. Based on SPY's performance of -12.20%, its performance is above average giving it a score of 100 of 100.

Technicals

RLAY
64/100

RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

VECT
89/100

VECT receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

RLAY
10/100

RLAY has missed earnings 8 times in the last 20 quarters.

VECT
100/100

VECT has missed earnings 1 times in the last 20 quarters.

Profit

RLAY
10/100

Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

VECT
10/100

Out of the last 13 quarters, VECT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

RLAY
53/100

RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

VECT
55/100

VECT has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Relay Therapeutics, Inc. Common Stock Summary

Nasdaq / RLAY

Healthcare

Biotechnology

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

VectivBio Holding AG Ordinary Shares Summary

Nasdaq / VECT

Healthcare

Biotechnology

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Power up your portfolio